Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12746736,QT(c),"There was a statistically significant greater mean QT(c) on haloperidol (421.6+/-20.1 ms) than on placebo (408.4+/-18.5 ms, P=0.0053) occurring 10 h post haloperidol/placebo administration.",Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746736/),ms,421.6,2816,DB00502,Haloperidol
,12746736,QT(c),"There was a statistically significant greater mean QT(c) on haloperidol (421.6+/-20.1 ms) than on placebo (408.4+/-18.5 ms, P=0.0053) occurring 10 h post haloperidol/placebo administration.",Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746736/),ms,408.4,2817,DB00502,Haloperidol
,12746736,elimination half-life,"Despite a statistically significant greater mean elimination half-life (19.1+/-3.6 vs 12.9+/-4.0 h, P=0.04) and lower mean apparent oral clearance (12.8+/-4.1 vs 27.0+/-11.3 ml/min/kg, P=0.02) of haloperidol in CYP2D6 PMs than in EMs, this exposure change did not translate into marked QT(c) changes from baseline that could be considered clinically important.",Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746736/),h,19.1,2818,DB00502,Haloperidol
,12746736,elimination half-life,"Despite a statistically significant greater mean elimination half-life (19.1+/-3.6 vs 12.9+/-4.0 h, P=0.04) and lower mean apparent oral clearance (12.8+/-4.1 vs 27.0+/-11.3 ml/min/kg, P=0.02) of haloperidol in CYP2D6 PMs than in EMs, this exposure change did not translate into marked QT(c) changes from baseline that could be considered clinically important.",Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746736/),h,12.9,2819,DB00502,Haloperidol
,12746736,apparent oral clearance,"Despite a statistically significant greater mean elimination half-life (19.1+/-3.6 vs 12.9+/-4.0 h, P=0.04) and lower mean apparent oral clearance (12.8+/-4.1 vs 27.0+/-11.3 ml/min/kg, P=0.02) of haloperidol in CYP2D6 PMs than in EMs, this exposure change did not translate into marked QT(c) changes from baseline that could be considered clinically important.",Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746736/),[ml] / [kg·min],12.8,2820,DB00502,Haloperidol
,12746736,apparent oral clearance,"Despite a statistically significant greater mean elimination half-life (19.1+/-3.6 vs 12.9+/-4.0 h, P=0.04) and lower mean apparent oral clearance (12.8+/-4.1 vs 27.0+/-11.3 ml/min/kg, P=0.02) of haloperidol in CYP2D6 PMs than in EMs, this exposure change did not translate into marked QT(c) changes from baseline that could be considered clinically important.",Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746736/),[ml] / [kg·min],27.0,2821,DB00502,Haloperidol
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB00502,Haloperidol
,9109178,haloperidol/haloperidol ratios,"Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 +/- 1.42 [S.D.] ng/ml vs. 1.10 +/- 0.46 ng/ml, P = 0.014 and 0.287 +/- 0.102 vs. 0.192 +/- 0.065, P = 0.030).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.287,10385,DB00502,Haloperidol
,9109178,haloperidol/haloperidol ratios,"Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 +/- 1.42 [S.D.] ng/ml vs. 1.10 +/- 0.46 ng/ml, P = 0.014 and 0.287 +/- 0.102 vs. 0.192 +/- 0.065, P = 0.030).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.192,10386,DB00502,Haloperidol
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),ng,8,10387,DB00502,Haloperidol
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),[ng] / [ml],5.83,10388,DB00502,Haloperidol
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.023,10389,DB00502,Haloperidol
,9109178,concentrations,"The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 +/- 2.91 ng/ml vs. 5.83 +/- 1.79 ng/ml, P = 0.066 and 0.023 +/- 0.017 vs. 0.011 +/- 0.010, P = 0.077).",Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109178/),,0.011,10390,DB00502,Haloperidol
,10857058,intrinsic clearance (Vmax/Km),"The oxidation rates of the (R)-isomers (3a and 4a) in the human liver microsomes were faster than those of the (S)-isomers (3b and 4b), and the R/S enantiomeric ratios of 3 and 4 for intrinsic clearance (Vmax/Km) were 1.40 and 3.10, respectively, showing that stereoselective oxidation occurred in human liver.","Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10857058/),,1.40,12234,DB00502,Haloperidol
,10857058,intrinsic clearance (Vmax/Km),"The oxidation rates of the (R)-isomers (3a and 4a) in the human liver microsomes were faster than those of the (S)-isomers (3b and 4b), and the R/S enantiomeric ratios of 3 and 4 for intrinsic clearance (Vmax/Km) were 1.40 and 3.10, respectively, showing that stereoselective oxidation occurred in human liver.","Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10857058/),,3.10,12235,DB00502,Haloperidol
<,17643323,C(max),"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),μM,40,15927,DB00502,Haloperidol
<,17643323,C(max),"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),μM,0.36,15928,DB00502,Haloperidol
<,17643323,C(max),"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),nM,825,15929,DB00502,Haloperidol
,17643323,peak increases,"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),ms,45,15930,DB00502,Haloperidol
,17643323,peak increases,"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),ms,31,15931,DB00502,Haloperidol
,17643323,peak increases,"Significant increases in QT(c) were evident with 10, 30 and 100 mg/kg of MOX (C(max)< or =40 microM), 0.3, 1 and 3 mg/kg of HAL (C(max)< or =0.36 microM) and 0.3 and 3 mg/kg of MK-499 (C(max)< or =825 nM) with peak increases of 45 (20%), 31 (13%), and 45 (19%) ms, respectively (p< or =0.05).","A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17643323/),ms,45,15932,DB00502,Haloperidol
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00502,Haloperidol
,32032570,IC50,IC50 values for rutin suspension and rutin NE were found to be 36.7 and 25.4 μg/ml respectively.,Role of Rutin Nanoemulsion in Ameliorating Oxidative Stress: Pharmacokinetic and Pharmacodynamics Studies. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32032570/),[μg] / [ml],36.7,19183,DB00502,Haloperidol
,32032570,IC50,IC50 values for rutin suspension and rutin NE were found to be 36.7 and 25.4 μg/ml respectively.,Role of Rutin Nanoemulsion in Ameliorating Oxidative Stress: Pharmacokinetic and Pharmacodynamics Studies. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32032570/),[μg] / [ml],25.4,19184,DB00502,Haloperidol
,23266466,zeta potential,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),m,40.3,19967,DB00502,Haloperidol
,23266466,loading capacity,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,37.8,19968,DB00502,Haloperidol
,23266466,entrapment efficiency,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,84.2,19969,DB00502,Haloperidol
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.47,19970,DB00502,Haloperidol
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.69,19971,DB00502,Haloperidol
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.05,19972,DB00502,Haloperidol
,23266466,drug targeting index,The drug targeting index and direct transport percentage for BRC loaded CS NPs following i.n. route were 6.3 ± 0.8 and 84.2% ± 1.9%.,"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,6.3,19973,DB00502,Haloperidol
,23266466,direct transport percentage,The drug targeting index and direct transport percentage for BRC loaded CS NPs following i.n. route were 6.3 ± 0.8 and 84.2% ± 1.9%.,"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,84.2,19974,DB00502,Haloperidol
,8666571,concentrations,"By the third week, mean plasma haloperidol concentrations from the decanoate injections were comparable with those of the 10-mg oral haloperidol treatment (7.95 +/- 4.94 ng/mL vs. 7.79 +/- 4.79 ng/mL).",A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666571/),ng,7.95,23302,DB00502,Haloperidol
,8666571,concentrations,"By the third week, mean plasma haloperidol concentrations from the decanoate injections were comparable with those of the 10-mg oral haloperidol treatment (7.95 +/- 4.94 ng/mL vs. 7.79 +/- 4.79 ng/mL).",A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666571/),[ng] / [ml],7.79,23303,DB00502,Haloperidol
,22753324,maximum plasma concentration,"The ISM formulation [20% PLGA in N-methyl-2-pyrrolidone (NMP)-peanut oil, 1:4] showed reduced maximum plasma concentration (60 versus 44 ng/mL) and longer release (30 days, plasma concentration of 8 ng/mL versus 20 days, plasma concentration of 6 ng/mL) compared with the ISI formulation (20% PLGA in NMP) after intramuscular injection in rats.",Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753324/),[ng] / [ml],60,23825,DB00502,Haloperidol
,22753324,maximum plasma concentration,"The ISM formulation [20% PLGA in N-methyl-2-pyrrolidone (NMP)-peanut oil, 1:4] showed reduced maximum plasma concentration (60 versus 44 ng/mL) and longer release (30 days, plasma concentration of 8 ng/mL versus 20 days, plasma concentration of 6 ng/mL) compared with the ISI formulation (20% PLGA in NMP) after intramuscular injection in rats.",Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753324/),[ng] / [ml],44,23826,DB00502,Haloperidol
,22753324,plasma concentration,"The ISM formulation [20% PLGA in N-methyl-2-pyrrolidone (NMP)-peanut oil, 1:4] showed reduced maximum plasma concentration (60 versus 44 ng/mL) and longer release (30 days, plasma concentration of 8 ng/mL versus 20 days, plasma concentration of 6 ng/mL) compared with the ISI formulation (20% PLGA in NMP) after intramuscular injection in rats.",Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753324/),[ng] / [ml],8,23827,DB00502,Haloperidol
,22753324,plasma concentration,"The ISM formulation [20% PLGA in N-methyl-2-pyrrolidone (NMP)-peanut oil, 1:4] showed reduced maximum plasma concentration (60 versus 44 ng/mL) and longer release (30 days, plasma concentration of 8 ng/mL versus 20 days, plasma concentration of 6 ng/mL) compared with the ISI formulation (20% PLGA in NMP) after intramuscular injection in rats.",Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753324/),[ng] / [ml],6,23828,DB00502,Haloperidol
,22753324,shelf lives,The shelf lives of both systems were found to be 2 years when stored at 4°C.,Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753324/),years,2,23829,DB00502,Haloperidol
,21034370,time to peak plasma concentration,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,2 - 4,26685,DB00502,Haloperidol
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,18,26686,DB00502,Haloperidol
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,33,26687,DB00502,Haloperidol
,12485307,repetition time (TR),"Because the chemical structure of haloperidol contains fluorine, in vivo 19F-magnetic resonance (MR) spectroscopy (repetition time (TR) = 1 s) and chemical shift imaging (CSI; TR = 1 s, pixel size = 15 x 15 mm) were performed in schizophrenic patients who were treated with haloperidol decanoate (three men and one woman) to measure its diachronic change at the injection point and visualize its local distribution after intramuscular injection.",19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485307/),s,1,27923,DB00502,Haloperidol
,12485307,TR,"Because the chemical structure of haloperidol contains fluorine, in vivo 19F-magnetic resonance (MR) spectroscopy (repetition time (TR) = 1 s) and chemical shift imaging (CSI; TR = 1 s, pixel size = 15 x 15 mm) were performed in schizophrenic patients who were treated with haloperidol decanoate (three men and one woman) to measure its diachronic change at the injection point and visualize its local distribution after intramuscular injection.",19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485307/),s,1,27924,DB00502,Haloperidol
,12485307,T1 time,19F signals (T1 time = 365 ms) were obtained at the haloperidol decanoate-injected region.,19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485307/),ms,365,27925,DB00502,Haloperidol
,16633141,area under the time-concentration curves (AUCs),Itraconazole pretreatment increased the mean area under the time-concentration curves (AUCs) of haloperidol by 55% compared to placebo pretreatment (21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],21.7,28806,DB00502,Haloperidol
,16633141,area under the time-concentration curves (AUCs),Itraconazole pretreatment increased the mean area under the time-concentration curves (AUCs) of haloperidol by 55% compared to placebo pretreatment (21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],33.5,28807,DB00502,Haloperidol
,16633141,AUC,The subjects with CYP2D6*10/*10 genotype showed 81% higher AUC compared to that of subjects with CYP2D6*1/*1 genotype (27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],27.6,28808,DB00502,Haloperidol
,16633141,AUC,The subjects with CYP2D6*10/*10 genotype showed 81% higher AUC compared to that of subjects with CYP2D6*1/*1 genotype (27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],50.2,28809,DB00502,Haloperidol
,16633141,AUC,"In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],21.7,28810,DB00502,Haloperidol
,16633141,AUC,"In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],66.7,28811,DB00502,Haloperidol
,16633141,oral clearance,"In the subjects with both CYP2D6*10 genotype and itraconazole pretreatment, however, the oral clearance was significantly decreased to 42% of subjects with wild genotype in the placebo pretreatment (4.7 +/- 3.6 vs 2.0 +/- 1.9 L/h/kg; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[l] / [h·kg],4.7,28812,DB00502,Haloperidol
,16633141,oral clearance,"In the subjects with both CYP2D6*10 genotype and itraconazole pretreatment, however, the oral clearance was significantly decreased to 42% of subjects with wild genotype in the placebo pretreatment (4.7 +/- 3.6 vs 2.0 +/- 1.9 L/h/kg; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[l] / [h·kg],2.0,28813,DB00502,Haloperidol
,2760816,relative bioavailability,"The relative bioavailability based on T:R1 or T:R2 ratios of AUCo infinity, AUCot, and Cmax was, in each case, within the acceptable range of 100 +/- 20%.",Comparative bioavailability of a new commercial tablet formulation and two lots of a reference formulation of haloperidol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760816/),%,100,35022,DB00502,Haloperidol
,2760816,relative bioavailability,"Also, the relative bioavailability of R1 compared with R2 was within 100 +/- 20% in terms of the above bioavailability parameters.",Comparative bioavailability of a new commercial tablet formulation and two lots of a reference formulation of haloperidol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760816/),%,100,35023,DB00502,Haloperidol
,1554878,total blood clearance,It was found that haloperidol was a high extraction ratio drug with a total blood clearance averaging 83 ml min-1 kg-1.,Linear pharmacokinetics of haloperidol in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554878/),[ml] / [kg·min],83,40165,DB00502,Haloperidol
,1554878,Vc,"The volumes of distribution were large with a mean of 5.5 1 kg-1 (Vc), 11.11 kg-1 (V beta), and 9.61 kg-1 (Vss), respectively.",Linear pharmacokinetics of haloperidol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554878/),[1] / [kg],5.5,40166,DB00502,Haloperidol
,1554878,V beta,"The volumes of distribution were large with a mean of 5.5 1 kg-1 (Vc), 11.11 kg-1 (V beta), and 9.61 kg-1 (Vss), respectively.",Linear pharmacokinetics of haloperidol in the rat. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554878/),1/[kg],11.11,40167,DB00502,Haloperidol
,1554878,Vss,"The volumes of distribution were large with a mean of 5.5 1 kg-1 (Vc), 11.11 kg-1 (V beta), and 9.61 kg-1 (Vss), respectively.",Linear pharmacokinetics of haloperidol in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554878/),1/[kg],9.61,40168,DB00502,Haloperidol
,1554878,terminal half-life,The terminal half-life was 1.5 h.,Linear pharmacokinetics of haloperidol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554878/),h,1.5,40169,DB00502,Haloperidol
,1554878,total blood clearance at steady-state,The total blood clearance at steady-state was concentration-independent within the investigated range of 5 to 20 ng ml-1.,Linear pharmacokinetics of haloperidol in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554878/),[ng] / [ml],5 to 20,40170,DB00502,Haloperidol
,28629145,Ki,"The PX-D and PX-E analogues acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogues displayed relatively mild MAO-B inhibition potencies, with inhibitor dissociation constants (Ki values) ranging from 0.25 to 10 μM.",Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629145/),μM,0.27 to 10,40246,DB00502,Haloperidol
,28629145,inhibitor dissociation constants (Ki values),"The PX-D and PX-E analogues acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogues displayed relatively mild MAO-B inhibition potencies, with inhibitor dissociation constants (Ki values) ranging from 0.25 to 10 μM.",Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629145/),μM,0.25 to 10,40247,DB00502,Haloperidol
,6149238,overall Cmin,"The overall Cmin of valproic acid with chlorpromazine (33.2 +/- 1.7 micrograms/ml, N = 25) was significantly (p less than 0.01) greater than without (27.1 +/- 1.4 micrograms/ml, N = 25).",The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[μg] / [ml],33.2,40333,DB00502,Haloperidol
,6149238,overall Cmin,"The overall Cmin of valproic acid with chlorpromazine (33.2 +/- 1.7 micrograms/ml, N = 25) was significantly (p less than 0.01) greater than without (27.1 +/- 1.4 micrograms/ml, N = 25).",The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[μg] / [ml],27.1,40334,DB00502,Haloperidol
,6149238,t1/2,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),h,15.4,40335,DB00502,Haloperidol
,6149238,t1/2,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),h,13.5,40336,DB00502,Haloperidol
,6149238,clearance,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[ml] / [h·kg],7.18,40337,DB00502,Haloperidol
,6149238,clearance,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[ml] / [h·kg],8.32,40338,DB00502,Haloperidol
,18576902,bioavailability,Mean (percent coefficient of variation) haloperidol bioavailability after intranasal administration was 63.8% (24.4%) compared with intravenous administration and 48.6% (29.4%) compared with intramuscular administration.,Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18576902/),%,63.8,41703,DB00502,Haloperidol
,18576902,bioavailability,Mean (percent coefficient of variation) haloperidol bioavailability after intranasal administration was 63.8% (24.4%) compared with intravenous administration and 48.6% (29.4%) compared with intramuscular administration.,Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18576902/),%,48.6,41704,DB00502,Haloperidol
,18576902,time to maximum concentration,"Median time to maximum concentration was 15 minutes after the intranasal dose compared with 37.5 and 15 minutes after the intramuscular and intravenous doses, respectively.",Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18576902/),min,15,41705,DB00502,Haloperidol
,18576902,time to maximum concentration,"Median time to maximum concentration was 15 minutes after the intranasal dose compared with 37.5 and 15 minutes after the intramuscular and intravenous doses, respectively.",Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18576902/),min,37.5,41706,DB00502,Haloperidol
,8930784,half-life (t1/2),"Significant changes in the pharmacokinetic parameters of haloperidol were not found in group I; a mean increase in the half-life (t1/2) of haloperidol from 21.5 to 28.1 hours was observed, but this finding was not statistically significant.",Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930784/),h,21.5,42408,DB00502,Haloperidol
,8930784,half-life (t1/2),"Significant changes in the pharmacokinetic parameters of haloperidol were not found in group I; a mean increase in the half-life (t1/2) of haloperidol from 21.5 to 28.1 hours was observed, but this finding was not statistically significant.",Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930784/),h,28.1,42409,DB00502,Haloperidol
,22926605,Plasma concentration,"Plasma concentration ranged from 0.13 to 4.11 μg/L, with one outlying measurement (21.43 μg/L).","Parkinsonism in elderly users of haloperidol: associated with dose, plasma concentration, and duration of use. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22926605/),[μg] / [l],0.13 to 4.11,44044,DB00502,Haloperidol
,22926605,Plasma concentration,"Plasma concentration ranged from 0.13 to 4.11 μg/L, with one outlying measurement (21.43 μg/L).","Parkinsonism in elderly users of haloperidol: associated with dose, plasma concentration, and duration of use. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22926605/),,21,44045,DB00502,Haloperidol
,7955815,daily,"The daily urinary excretion of HPP+ and RHPP+ accounted for 0.40% +/- 0.18% and 2.3% +/- 1.4% of the haloperidol dose, respectively.",Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955815/),%,0.40,47631,DB00502,Haloperidol
,7955815,urinary excretion,"The daily urinary excretion of HPP+ and RHPP+ accounted for 0.40% +/- 0.18% and 2.3% +/- 1.4% of the haloperidol dose, respectively.",Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955815/),%,0.40,47632,DB00502,Haloperidol
,7955815,urinary excretion,"The daily urinary excretion of HPP+ and RHPP+ accounted for 0.40% +/- 0.18% and 2.3% +/- 1.4% of the haloperidol dose, respectively.",Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955815/),%,2.3,47633,DB00502,Haloperidol
,7955815,renal clearance,"The renal clearance of each species was 4.5 +/- 2.5 and 11.3 +/- 5.3 L/hr, respectively.",Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955815/),[l] / [h],4.5,47634,DB00502,Haloperidol
,7955815,renal clearance,"The renal clearance of each species was 4.5 +/- 2.5 and 11.3 +/- 5.3 L/hr, respectively.",Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955815/),[l] / [h],11.3,47635,DB00502,Haloperidol
,3060191,Plasma concentrations,"4. Plasma concentrations of nalbuphine expressed as morphine equivalents ranged from 5 to 52 ng ml-1, indicating considerable mu-opiate affinity.","Psychomotor, respiratory and neuroendocrinological effects of nalbuphine and haloperidol, alone and in combination, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3060191/),[ng] / [ml],5 to 52,48419,DB00502,Haloperidol
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00502,Haloperidol
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00502,Haloperidol
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00502,Haloperidol
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00502,Haloperidol
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00502,Haloperidol
,25459927,flow rate,"After solid phase extraction of 50.0 μL rat plasma in 96 well plate, a baseline resolution of arotinolol enantiomers was achieved on a CHIRALPAK AD-H column using the mobile phase of n-hexane and ethanol in 0.02% diethylamine (20:80, v/v) at a flow rate of 0.550 mL/min within 11.0 min.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),[ml] / [min],0.550,59150,DB00502,Haloperidol
,25459927,m/z,Acquisition of mass spectrometric data was performed on a triple-quadrupole mass spectrometer in multiple-reaction-monitoring (MRM) mode with an ESI source using the transition m/z 372.1 → 316.1 for (±)-arotinolol and m/z 376.1 → 165.1 for haloperidol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),,376.1,59151,DB00502,Haloperidol
,25459927,m/z,Acquisition of mass spectrometric data was performed on a triple-quadrupole mass spectrometer in multiple-reaction-monitoring (MRM) mode with an ESI source using the transition m/z 372.1 → 316.1 for (±)-arotinolol and m/z 376.1 → 165.1 for haloperidol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),,165.1,59152,DB00502,Haloperidol
,25459927,Accuracy,Accuracy varied from 0.0% to 7.0% for R-(-)-arotinolol and 5.0-10.0% for S-(+)-arotinolol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,0,59153,DB00502,Haloperidol
,25459927,Accuracy,Accuracy varied from 0.0% to 7.0% for R-(-)-arotinolol and 5.0-10.0% for S-(+)-arotinolol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,7.0,59154,DB00502,Haloperidol
,25459927,Accuracy,Accuracy varied from 0.0% to 7.0% for R-(-)-arotinolol and 5.0-10.0% for S-(+)-arotinolol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,5.0-10.0,59155,DB00502,Haloperidol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,87.2,59156,DB00502,Haloperidol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,99.2,59157,DB00502,Haloperidol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,88.0,59158,DB00502,Haloperidol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,92.4,59159,DB00502,Haloperidol
,7542676,absolute oral bioavailability,"The absolute oral bioavailability of risperidone is nearly 70%, and after oral administration, it is rapidly absorbed with the plasma level reaching a peak at about 1 h.","A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7542676/),%,70,63037,DB00502,Haloperidol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.7,63805,DB00502,Haloperidol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.9,63806,DB00502,Haloperidol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.8,63807,DB00502,Haloperidol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.4,63808,DB00502,Haloperidol
,19879867,pA(2),"In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA(2)=7.2) at cloned human tachykinin NK(3) receptor whereas GSK256471 diminished the neurokinin B-induced E(max) response, indicative of non-surmountable antagonist pharmacology (pA(2)=9.2).",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.2,63809,DB00502,Haloperidol
,19879867,pA(2),"In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA(2)=7.2) at cloned human tachykinin NK(3) receptor whereas GSK256471 diminished the neurokinin B-induced E(max) response, indicative of non-surmountable antagonist pharmacology (pA(2)=9.2).",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,9.2,63810,DB00502,Haloperidol
,19879867,apparent pK(B),"GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pK(B)=8.1), whilst GSK256471 abolished the agonist-induced response.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.1,63811,DB00502,Haloperidol
,19879867,ED(50),"Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK(3) receptor occupancy in medial prefrontal cortex (ED(50) values of 0.8 and 0.9 mg/kg, i.p., respectively) and the dose-dependent attenuation of agonist-induced ""wet dog shake"" behaviours in guinea pigs.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),[mg] / [kg],0.8,63812,DB00502,Haloperidol
,19879867,ED(50),"Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK(3) receptor occupancy in medial prefrontal cortex (ED(50) values of 0.8 and 0.9 mg/kg, i.p., respectively) and the dose-dependent attenuation of agonist-induced ""wet dog shake"" behaviours in guinea pigs.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),[mg] / [kg],0.9,63813,DB00502,Haloperidol
,7658345,peak concentration (Cmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[ng] / [ml],7.15,67443,DB00502,Haloperidol
,7658345,time to Cmax (Tmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),h,1.32,67444,DB00502,Haloperidol
,7658345,time to Cmax (Tmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[1] / [h],2.07,67445,DB00502,Haloperidol
,7658345,rate of absorption (Ka),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),h,1.32,67446,DB00502,Haloperidol
,7658345,rate of absorption (Ka),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[1] / [h],2.07,67447,DB00502,Haloperidol
,7658345,area under the curve from 0 to 72 h (AUC0-72),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[h·ng] / [ml],201,67448,DB00502,Haloperidol
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,2,67906,DB00502,Haloperidol
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,6.8,67907,DB00502,Haloperidol
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,15,67908,DB00502,Haloperidol
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,58,67909,DB00502,Haloperidol
,8321085,half-life of washout,[123I]Epidepride was displaced by haloperidol (0.1 and 1 mg/kg) with a half-life of washout of 55 min.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,55,67910,DB00502,Haloperidol
,8321085,KD,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),pM,46,67911,DB00502,Haloperidol
,8321085,Bmax,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),[pM] / [g·tissue],33,67912,DB00502,Haloperidol
,8321085,KD,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),pM,25,67913,DB00502,Haloperidol
,8321085,Bmax,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),[pM] / [g·tissue],32,67914,DB00502,Haloperidol
,8321085,half-life,In vitro kinetic analysis of association and dissociation curves revealed a half-life for receptor dissociation at 37 degrees C of 15 min and 79-90 min at 25 degrees C.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,15,67915,DB00502,Haloperidol
,8321085,half-life,In vitro kinetic analysis of association and dissociation curves revealed a half-life for receptor dissociation at 37 degrees C of 15 min and 79-90 min at 25 degrees C.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,79-90,67916,DB00502,Haloperidol
,2864156,apparent elimination half-life,The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,3.5 to 4,72901,DB00502,Haloperidol
,2864156,half-time of the apparent first-order decline of plasma concentrations,The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,3.5 to 4,72902,DB00502,Haloperidol
,2864156,apparent half-life,The decanoate produces an early high peak which occurs during the first day and then declines with an apparent half-life ranging from 6.8 to 9.6 days following a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,6.8 to 9.6,72903,DB00502,Haloperidol
,2864156,apparent half-life,"After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks.",Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,14.3,72904,DB00502,Haloperidol
,2864156,time to reach steady-state,"After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks.",Clinical pharmacokinetics of the depot antipsychotics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),weeks,4 to 6,72905,DB00502,Haloperidol
,26000388,zeta potential,"In the present investigation, soft nanocarriers, viz., microemulsion of ropinirole with the globule size of 160.2 ± 3.87 nm and zeta potential of -4.24 mV was explored for transdermal application.",Colloidal soft nanocarrier for transdermal delivery of dopamine agonist: ex vivo and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26000388/),mv,-4.24,74306,DB00502,Haloperidol
,8463444,elimination half-life,"The range of observed elimination half-life was broad, between 8.5 and 66.6 hours, with a mean of 19.5 hours.","The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8463444/),h,8.5 and 66.6,75414,DB00502,Haloperidol
,8463444,elimination half-life,"The range of observed elimination half-life was broad, between 8.5 and 66.6 hours, with a mean of 19.5 hours.","The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8463444/),h,19.5,75415,DB00502,Haloperidol
,3108922,steady state concentration ratio,The steady state concentration ratio between blood and plasma was determined and found to be 0.79 +/- 0.03.,Pharmacokinetics of haloperidol in psychotic patients. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),,0.79,83864,DB00502,Haloperidol
,3108922,blood clearance,The blood clearance was then calculated to be 550 +/- 133 ml/min.,Pharmacokinetics of haloperidol in psychotic patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),[ml] / [min],550,83865,DB00502,Haloperidol
,3108922,hepatic extraction ratio,The mean hepatic extraction ratio was intermediate (0.37).,Pharmacokinetics of haloperidol in psychotic patients. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),,0.37,83866,DB00502,Haloperidol
,3108922,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was large (7.9 +/- 2.5 l/kg).,Pharmacokinetics of haloperidol in psychotic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),[l] / [kg],7.9,83867,DB00502,Haloperidol
,3108922,terminal half-life,The terminal half-life was 18.8 h after intravenous and 18.1 h after oral administration.,Pharmacokinetics of haloperidol in psychotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),h,18.8,83868,DB00502,Haloperidol
,3108922,terminal half-life,The terminal half-life was 18.8 h after intravenous and 18.1 h after oral administration.,Pharmacokinetics of haloperidol in psychotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),h,18.1,83869,DB00502,Haloperidol
,3108922,oral bioavailability,The oral bioavailability (0.60 +/- 0.18) were in accordance with previous results in healthy subjects.,Pharmacokinetics of haloperidol in psychotic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),,0.60,83870,DB00502,Haloperidol
,3108922,lag time,A mean lag time after oral dose was 1.3 +/- 1.1 h and a longer absorption half-life (1.9 +/- 1.4 h) was found in the patients compared with healthy volunteers.,Pharmacokinetics of haloperidol in psychotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),h,1.3,83871,DB00502,Haloperidol
,3108922,absorption half-life,A mean lag time after oral dose was 1.3 +/- 1.1 h and a longer absorption half-life (1.9 +/- 1.4 h) was found in the patients compared with healthy volunteers.,Pharmacokinetics of haloperidol in psychotic patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108922/),h,1.9,83872,DB00502,Haloperidol
,7751433,dose-normalized Cmax,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],6.40,88551,DB00502,Haloperidol
,7751433,dose-normalized Cmax,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],5.75,88552,DB00502,Haloperidol
,7751433,dose-normalized Cmin,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],2.00,88553,DB00502,Haloperidol
,7751433,dose-normalized Cmin,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],1.90,88554,DB00502,Haloperidol
,7751433,dose-normalized AUC,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[h·ng] / [ml],85.97,88555,DB00502,Haloperidol
,7751433,dose-normalized AUC,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[h·ng] / [ml],68.48,88556,DB00502,Haloperidol
,7751433,CL/f,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[l] / [h],78.23,88557,DB00502,Haloperidol
,7751433,CL/f,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[l] / [h],104.7,88558,DB00502,Haloperidol
,7751433,AUC ratios,"Mean AUC ratios of reduced haloperidol to haloperidol (0.18) in the presence of alosetron were similar to values obtained in the absence of alosetron, indicating that alosetron had no influence on the metabolism of haloperidol.",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),,0.18,88559,DB00502,Haloperidol
,3965439,half-lives,Mean (+/- SD) half-lives were 17.5 +/- 8.7 hours for oral administration and 15.1 +/- 2.5 hours for intravenous; bioavailability was 0.64 +/- 0.23.,Elimination half-life and bioavailability of haloperidol in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965439/),h,17.5,88648,DB00502,Haloperidol
,3965439,half-lives,Mean (+/- SD) half-lives were 17.5 +/- 8.7 hours for oral administration and 15.1 +/- 2.5 hours for intravenous; bioavailability was 0.64 +/- 0.23.,Elimination half-life and bioavailability of haloperidol in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965439/),h,15.1,88649,DB00502,Haloperidol
,3965439,bioavailability,Mean (+/- SD) half-lives were 17.5 +/- 8.7 hours for oral administration and 15.1 +/- 2.5 hours for intravenous; bioavailability was 0.64 +/- 0.23.,Elimination half-life and bioavailability of haloperidol in schizophrenic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965439/),,0.64,88650,DB00502,Haloperidol
,24113674,steady-state effective plasma ha,"Based on the PKPD analysis, the recommended oral dose of haloperidol to achieve a 30% reduction in PANSS score from baseline is 5.6 mg/d, and the corresponding steady-state effective plasma haloperidol exposure is 2.7 ng/mL.",Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24113674/),[ng] / [ml],2.7,89197,DB00502,Haloperidol
,8834418,Css,"Drug-free schizophrenic and schizo-affective patients were blindly and randomly assigned to achieve a low (< 5 ng/ml), medium (10-18 ng/ml), or high (> 25 ng/ml) Css range of HPDL.",Prediction of haloperidol steady-state levels in plasma after a single test dose. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8834418/),[ng] / [ml],25,89780,DB00502,Haloperidol
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB00502,Haloperidol
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB00502,Haloperidol
,12737534,steady-state plasma concentration (cp(ss)),The pharmacokinetic parameters in rabbit model showed a very significant prolongation of action up to 72 hr with steady-state plasma concentration (cp(ss)) of 11.58 ng/mL.,Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12737534/),[ng] / [ml],11.58,95506,DB00502,Haloperidol
,18810393,blood serum concentration,"After administration via drinking water in saline-injected control animals, the hal blood serum concentration was 2.6 +/- 0.45 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],2.6,99177,DB00502,Haloperidol
,18810393,serum concentration,"In ket-injected animals, the mean serum concentration of hal amounted to 1.2 +/- 0.44 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],1.2,99178,DB00502,Haloperidol
,9829293,serum concentrations,3. Mean serum concentrations were 8 ng/ml for haloperidol and 21 ng/ml for clozapine.,"Chronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioral studies and serum level determination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829293/),[ng] / [ml],8,100928,DB00502,Haloperidol
,9829293,serum concentrations,3. Mean serum concentrations were 8 ng/ml for haloperidol and 21 ng/ml for clozapine.,"Chronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioral studies and serum level determination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829293/),[ng] / [ml],21,100929,DB00502,Haloperidol
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.13,105121,DB00502,Haloperidol
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.27,105122,DB00502,Haloperidol
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0,105123,DB00502,Haloperidol
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.24,105124,DB00502,Haloperidol
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.34,105125,DB00502,Haloperidol
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.33,105126,DB00502,Haloperidol
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.58,105127,DB00502,Haloperidol
,22588199,t(max),A log brain/plasma concentration ratio at a t(max) of 1.48 suggests that SYA013 readily crosses the blood brain barrier (BBB).,"Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588199/),,1.48,109056,DB00502,Haloperidol
,2343070,clearances,"Using a general pharmacokinetic model for the interconversion process, the clearances of haloperidol and reduced haloperidol are 1.15 +/- 0.32 l/h/kg and 0.76 +/- 54 l/h/kg, respectively.",Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2343070/),[l] / [h·kg],1.15,112702,DB00502,Haloperidol
,2343070,clearances,"Using a general pharmacokinetic model for the interconversion process, the clearances of haloperidol and reduced haloperidol are 1.15 +/- 0.32 l/h/kg and 0.76 +/- 54 l/h/kg, respectively.",Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2343070/),[l] / [h·kg],0.76,112703,DB00502,Haloperidol
,18571772,plasma half-life,The tracer had a plasma half-life of 77+/-1.7min and was rapidly taken up by all brain areas.,"Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors-the cases of ketamine and haloperidol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18571772/),min,77,112939,DB00502,Haloperidol
,7767316,half-life,"The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7% ID/g) at 5 min, followed by clearance with a half-life of 16.1 min.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),min,16.1,112974,DB00502,Haloperidol
,7767316,ratio,"As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),,7.4,112975,DB00502,Haloperidol
,7767316,ED50,[11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum.,[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),[mg] / [kg],0.3,112976,DB00502,Haloperidol
,15538130,half-life,"In normal subjects after a single oral dose, haloperidol half-life has been reported to range 14.5-36.7 hours (or up to 1.5 days).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),h,14.5-36.7,112987,DB00502,Haloperidol
up to,15538130,half-life,"In normal subjects after a single oral dose, haloperidol half-life has been reported to range 14.5-36.7 hours (or up to 1.5 days).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,1.5,112988,DB00502,Haloperidol
up to,15538130,half-lives,"After chronic administration, half-lives of up to 21 days have been reported.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,21,112989,DB00502,Haloperidol
,15538130,half-life,"The geometric mean for haloperidol half-life and detectable levels duration were 3.9 and 13.8 days, respectively.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3.9,112990,DB00502,Haloperidol
,15538130,detectable levels duration,"The geometric mean for haloperidol half-life and detectable levels duration were 3.9 and 13.8 days, respectively.",Haloperidol half-life after chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,13.8,112991,DB00502,Haloperidol
<,15538130,half-lives,"Within 31 subjects, 58% (18/31) had half-lives <3 days (1.2-2.3 days) and 42% (13/31) had half-lives > or =3 days.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112992,DB00502,Haloperidol
> or =,15538130,half-lives,"Within 31 subjects, 58% (18/31) had half-lives <3 days (1.2-2.3 days) and 42% (13/31) had half-lives > or =3 days.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112993,DB00502,Haloperidol
longer,15538130,half-lives,Two of 3 patients with half-lives longer than 30 days (720 hours) and levels detectable >2 months had received haloperidol decanoate.,Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,30,112994,DB00502,Haloperidol
>,15538130,half-lives,"Five patients who received haloperidol decanoate in the prior year were excluded from a comparison between patients with long haloperidol half-lives (> or =3 days, n = 10) and patients with short half-lives (<3 days, n = 16).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,or,112995,DB00502,Haloperidol
>,15538130,half-lives,"Five patients who received haloperidol decanoate in the prior year were excluded from a comparison between patients with long haloperidol half-lives (> or =3 days, n = 10) and patients with short half-lives (<3 days, n = 16).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112996,DB00502,Haloperidol
<,15538130,half-lives,"Five patients who received haloperidol decanoate in the prior year were excluded from a comparison between patients with long haloperidol half-lives (> or =3 days, n = 10) and patients with short half-lives (<3 days, n = 16).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112997,DB00502,Haloperidol
> or =,15538130,half-lives,CYP3A5 genotype did not appear to influence haloperidol half-life but the two CYP2D6 poor metabolizer had half-lives > or =3 days.,Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112998,DB00502,Haloperidol
,26579417,drug release,In vitro drug release was found to be 94.16±4.78% after 24 h and was fitted to the Higuchi model with a very high correlation coefficient (R (2)=0.9941).,Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579417/),%,94.16,117356,DB00502,Haloperidol
,26579417,brain/blood ratio,"The brain/blood ratio at 0.5 h for HP-SLNs i.n., HP sol.",Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579417/),,0,117357,DB00502,Haloperidol
,26579417,maximum concentration (C max),"The maximum concentration (C max) in brain achieved from i.n. administration of HP-SLNs (329.17±20.89 ng/mL, T max 2 h) was significantly higher than that achieved after i.v. (76.95±7.62 ng/mL, T max 1 h), and i.n. (90.13±6.28 ng/mL, T max 2 h) administration of HP sol.",Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579417/),[ng] / [ml],329.17,117358,DB00502,Haloperidol
,26579417,maximum concentration (C max),"The maximum concentration (C max) in brain achieved from i.n. administration of HP-SLNs (329.17±20.89 ng/mL, T max 2 h) was significantly higher than that achieved after i.v. (76.95±7.62 ng/mL, T max 1 h), and i.n. (90.13±6.28 ng/mL, T max 2 h) administration of HP sol.",Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579417/),[ng] / [ml],76.95,117359,DB00502,Haloperidol
,26579417,T max,"The maximum concentration (C max) in brain achieved from i.n. administration of HP-SLNs (329.17±20.89 ng/mL, T max 2 h) was significantly higher than that achieved after i.v. (76.95±7.62 ng/mL, T max 1 h), and i.n. (90.13±6.28 ng/mL, T max 2 h) administration of HP sol.",Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579417/),h,2,117360,DB00502,Haloperidol
,26579417,T max,"The maximum concentration (C max) in brain achieved from i.n. administration of HP-SLNs (329.17±20.89 ng/mL, T max 2 h) was significantly higher than that achieved after i.v. (76.95±7.62 ng/mL, T max 1 h), and i.n. (90.13±6.28 ng/mL, T max 2 h) administration of HP sol.",Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579417/),h,1,117361,DB00502,Haloperidol
,26579417,drug-targeting efficiency,The highest drug-targeting efficiency (2362.43%) and direct transport percentage (95.77%) was found with HP-SLNs as compared to the other formulations.,Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579417/),%,2362.43,117362,DB00502,Haloperidol
,8504292,half-life,"Planar imaging studies with [123I]5 revealed significant accumulation of radioactivity within the monkey brain, with a half-life of 6 h.",Synthesis and biological evaluation of radioiodinated N-2-(4-piperidyl)ethyl benzamides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504292/),h,6,126135,DB00502,Haloperidol
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB00502,Haloperidol
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB00502,Haloperidol
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB00502,Haloperidol
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB00502,Haloperidol
,2349370,absorption half-life,"Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections.",Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2349370/),weeks,4,129015,DB00502,Haloperidol
,11999910,prola,"The prolactin concentration in plasma during bromperidol treatment (median and range; 24 and 7-93 ng/ml, respectively) was significantly (P< .01) lower than during haloperidol treatment (32 and 8-102 ng/ml), although the difference was small.",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),[ng] / [ml],24,132587,DB00502,Haloperidol
,11999910,prola,"The prolactin concentration in plasma during bromperidol treatment (median and range; 24 and 7-93 ng/ml, respectively) was significantly (P< .01) lower than during haloperidol treatment (32 and 8-102 ng/ml), although the difference was small.",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),[ng] / [ml],7-93,132588,DB00502,Haloperidol
,11999910,prola,"The prolactin concentration in plasma during bromperidol treatment (median and range; 24 and 7-93 ng/ml, respectively) was significantly (P< .01) lower than during haloperidol treatment (32 and 8-102 ng/ml), although the difference was small.",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),[ng] / [ml],32,132589,DB00502,Haloperidol
,11999910,concentration,"The prolactin concentration in plasma during bromperidol treatment (median and range; 24 and 7-93 ng/ml, respectively) was significantly (P< .01) lower than during haloperidol treatment (32 and 8-102 ng/ml), although the difference was small.",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),[ng] / [ml],24,132590,DB00502,Haloperidol
,11999910,concentration,"The prolactin concentration in plasma during bromperidol treatment (median and range; 24 and 7-93 ng/ml, respectively) was significantly (P< .01) lower than during haloperidol treatment (32 and 8-102 ng/ml), although the difference was small.",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),[ng] / [ml],7-93,132591,DB00502,Haloperidol
,11999910,concentration,"The prolactin concentration in plasma during bromperidol treatment (median and range; 24 and 7-93 ng/ml, respectively) was significantly (P< .01) lower than during haloperidol treatment (32 and 8-102 ng/ml), although the difference was small.",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),[ng] / [ml],32,132592,DB00502,Haloperidol
,11999910,concentration,"The prolactin concentration in plasma during bromperidol treatment (median and range; 24 and 7-93 ng/ml, respectively) was significantly (P< .01) lower than during haloperidol treatment (32 and 8-102 ng/ml), although the difference was small.",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),[ng] / [ml],8-102,132593,DB00502,Haloperidol
,11999910,plasma concentration,"The mean (+/- S.D.) plasma concentration of bromperidol was significantly lower than that of haloperidol (20.8+/-8.0 vs. 28.0+/-13.1 nmol/l, P<.05).",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),,20,132594,DB00502,Haloperidol
,11999910,plasma concentration,"The mean (+/- S.D.) plasma concentration of bromperidol was significantly lower than that of haloperidol (20.8+/-8.0 vs. 28.0+/-13.1 nmol/l, P<.05).",Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999910/),,28.0,132595,DB00502,Haloperidol
,2689040,bioavailability,Large doses of haloperidol can safely be given intravenously and intramuscularly for rapid neuroleptisation; the bioavailability of this agent administered orally ranges from 60 to 65%.,Pharmacokinetics of haloperidol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2689040/),%,60 to 65,134198,DB00502,Haloperidol
,2689040,elimination half-life,"The elimination half-life is about 3 weeks, and the time to steady-state is about 3 months.",Pharmacokinetics of haloperidol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2689040/),weeks,3,134199,DB00502,Haloperidol
,2689040,time to steady-state,"The elimination half-life is about 3 weeks, and the time to steady-state is about 3 months.",Pharmacokinetics of haloperidol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2689040/),month,3,134200,DB00502,Haloperidol
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.96,134211,DB00502,Haloperidol
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.73,134212,DB00502,Haloperidol
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.25,134213,DB00502,Haloperidol
,26342056,m/z,"The transitions used were m/z 388.0→343.0, 374.0→195.0 and 380.1→169.0 for TMB, nor-TMB and IS, respectively.",An Automated Method for the Determination of Trimebutine and N-Mono-Desmethyl Trimebutine by On-Line Turbulent Flow Coupled with Liquid Chromatography-Tandem Mass Spectrometry in Human Plasma: Application to a Fatal Poisoning Case with Toxicokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342056/),,388.0,136109,DB00502,Haloperidol
,26342056,m/z,"The transitions used were m/z 388.0→343.0, 374.0→195.0 and 380.1→169.0 for TMB, nor-TMB and IS, respectively.",An Automated Method for the Determination of Trimebutine and N-Mono-Desmethyl Trimebutine by On-Line Turbulent Flow Coupled with Liquid Chromatography-Tandem Mass Spectrometry in Human Plasma: Application to a Fatal Poisoning Case with Toxicokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342056/),,343.0,136110,DB00502,Haloperidol
,26342056,m/z,"The transitions used were m/z 388.0→343.0, 374.0→195.0 and 380.1→169.0 for TMB, nor-TMB and IS, respectively.",An Automated Method for the Determination of Trimebutine and N-Mono-Desmethyl Trimebutine by On-Line Turbulent Flow Coupled with Liquid Chromatography-Tandem Mass Spectrometry in Human Plasma: Application to a Fatal Poisoning Case with Toxicokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342056/),,374.0,136111,DB00502,Haloperidol
,26342056,m/z,"The transitions used were m/z 388.0→343.0, 374.0→195.0 and 380.1→169.0 for TMB, nor-TMB and IS, respectively.",An Automated Method for the Determination of Trimebutine and N-Mono-Desmethyl Trimebutine by On-Line Turbulent Flow Coupled with Liquid Chromatography-Tandem Mass Spectrometry in Human Plasma: Application to a Fatal Poisoning Case with Toxicokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342056/),,195.0,136112,DB00502,Haloperidol
,26342056,m/z,"The transitions used were m/z 388.0→343.0, 374.0→195.0 and 380.1→169.0 for TMB, nor-TMB and IS, respectively.",An Automated Method for the Determination of Trimebutine and N-Mono-Desmethyl Trimebutine by On-Line Turbulent Flow Coupled with Liquid Chromatography-Tandem Mass Spectrometry in Human Plasma: Application to a Fatal Poisoning Case with Toxicokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342056/),,380.1,136113,DB00502,Haloperidol
,26342056,m/z,"The transitions used were m/z 388.0→343.0, 374.0→195.0 and 380.1→169.0 for TMB, nor-TMB and IS, respectively.",An Automated Method for the Determination of Trimebutine and N-Mono-Desmethyl Trimebutine by On-Line Turbulent Flow Coupled with Liquid Chromatography-Tandem Mass Spectrometry in Human Plasma: Application to a Fatal Poisoning Case with Toxicokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342056/),,169.0,136114,DB00502,Haloperidol
,7334810,apparent volume of distribution,"The apparent volume of distribution for the two monkeys examined was 5.87 L kg-1 and 7.37 L kg-1, considerably smaller than in man, a difference almost entirely due to a much smaller tissue compartment.",Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7334810/),[l] / [kg],5.87,141579,DB00502,Haloperidol
,7334810,apparent volume of distribution,"The apparent volume of distribution for the two monkeys examined was 5.87 L kg-1 and 7.37 L kg-1, considerably smaller than in man, a difference almost entirely due to a much smaller tissue compartment.",Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7334810/),[l] / [kg],7.37,141580,DB00502,Haloperidol
,7334810,biological half-life,The biological half-life of 15.97 hr and 7.56 hr was similar to man.,Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7334810/),h,15.97,141581,DB00502,Haloperidol
,7334810,biological half-life,The biological half-life of 15.97 hr and 7.56 hr was similar to man.,Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7334810/),h,7.56,141582,DB00502,Haloperidol
,7334810,hepatic extraction ratio,"The mean hepatic extraction ratio was calculated to be 0.032 and 0.056, and the data suggested that hepatic metabolism of haloperidol may be of lesser importance in rhesus monkey than in man.",Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7334810/),,0.032,141583,DB00502,Haloperidol
,7334810,hepatic extraction ratio,"The mean hepatic extraction ratio was calculated to be 0.032 and 0.056, and the data suggested that hepatic metabolism of haloperidol may be of lesser importance in rhesus monkey than in man.",Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7334810/),,0.056,141584,DB00502,Haloperidol
,12404702,bioavailability,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,48,142126,DB00502,Haloperidol
,12404702,protein binding,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,17,142127,DB00502,Haloperidol
,12404702,elimination half-life,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),h,12,142128,DB00502,Haloperidol
,3436339,half-life,"These lymph node levels became maximum 16 days after administration and declined gradually with half-life (around 14 days) similar to those of plasma total radioactivity, haloperidol decanoate and haloperidol.",Absorption of intramuscularly administered [14C]haloperidol decanoate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436339/),d,14,142326,DB00502,Haloperidol
,8461270,elimination half-life,The mean elimination half-life for haloperidol was 27.4 +/- 8.6 days (range 19.0-47.0 days).,Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461270/),d,27.4,143840,DB00502,Haloperidol
,15039292,clearance,"Using an alternative method, based on normalization of in vitro human data with the ratio of in vivo to in vitro animal data, the in vivo clearance in humans was predicted to be 0.39 l/h/kg.","Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039292/),[l] / [h·kg],0.39,147080,DB00502,Haloperidol
,12450541,recoveries,"The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively.",Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12450541/),%,96.8,147712,DB00502,Haloperidol
,12450541,recoveries,"The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively.",Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12450541/),%,99.4,147713,DB00502,Haloperidol
,15918525,AUC0-60h,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[h·ng] / [ml],17.21,154001,DB00502,Haloperidol
,15918525,AUC0-60h,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[h·ng] / [ml],17.31,154002,DB00502,Haloperidol
,15918525,Cmax,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[ng] / [ml],0.87,154003,DB00502,Haloperidol
,15918525,Cmax,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[ng] / [ml],0.85,154004,DB00502,Haloperidol
,15918525,AUCinf,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[h·ng] / [ml],21.75,154005,DB00502,Haloperidol
,15918525,t1/2,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),l,12.90,154006,DB00502,Haloperidol
,15918525,Vd/F,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),l,12.90,154007,DB00502,Haloperidol
,15918525,CL/F,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[l] / [h],0.26,154008,DB00502,Haloperidol
,15918525,CL/F,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[l] / [h],0.31,154009,DB00502,Haloperidol
,3783453,half-life,"Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1- butanone), a reference compound used for model development, disappeared from the intestinal lumen with a half-life of 14 +/- 3 min.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,14,155304,DB00502,Haloperidol
,3783453,t1/2,"When the antiarthritic agent, tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetate dihydrate), was studied in the preparation, it was rapidly absorbed (t1/2 for disappearance from the intestinal lumen = 8 min), achieved plasma concentrations comparable to in vivo data, and underwent little presystemic elimination.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,8,155305,DB00502,Haloperidol
,3783453,t1/2,"In contrast, fenoctimine sulfate (4-(diphenylmethyl)-1-[(octylimino)methyl]piperidine sulfate), an antisecretory compound, disappeared more slowly from the intestinal lumen (t1/2 = 60 min), was present in portal plasma, but was not detected in systemic plasma.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,60,155306,DB00502,Haloperidol
,3783453,t1/2,"Tolmetin glycine amide (N-([1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl)glycine), a tolmetin prodrug, disappeared from the intestinal lumen very slowly (t1/2 approximately 3 h) compared with the other agents tested.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),h,3,155307,DB00502,Haloperidol
,1585408,plasma half-life,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),h,29.4,159562,DB00502,Haloperidol
,1585408,plasma half-life,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),h,16.3,159563,DB00502,Haloperidol
,1585408,clearance,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),[l] / [h·kg],1.16,159564,DB00502,Haloperidol
,1585408,clearance,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),[l] / [h·kg],2.49,159565,DB00502,Haloperidol
,1524655,elimination,There were also interindividual variabilities in the elimination of reduced haloperidol (0.37 +/- 0.20 L/hr/kg) and the N-dealkylation pathway (0.74 +/- 0.36 L/hr/kg).,Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524655/),[l] / [h·kg],0.37,160304,DB00502,Haloperidol
,1524655,elimination,There were also interindividual variabilities in the elimination of reduced haloperidol (0.37 +/- 0.20 L/hr/kg) and the N-dealkylation pathway (0.74 +/- 0.36 L/hr/kg).,Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524655/),[l] / [h·kg],0.74,160305,DB00502,Haloperidol
,1524655,concentration ratio,The reduced haloperidol to haloperidol concentration ratio (0.40 +/- 0.16) after the 4-week therapy is related to individual variabilities in the interconversion process and the N-dealkylation pathway of haloperidol.,Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524655/),,0.40,160306,DB00502,Haloperidol
,8940718,Ki,"Sites labeled by 4-[125I]PEMP in guinea pig brain membranes showed high affinity for BD1008, haloperidol, and (+)-pentazocine (Ki = 5.06 +/- 0.40, 32.6 +/- 2.75, and 48.1 +/- 8.60 nM, respectively), which is consistent with sigma receptor pharmacology.","Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8940718/),nM,5.06,167030,DB00502,Haloperidol
,8940718,Ki,"Sites labeled by 4-[125I]PEMP in guinea pig brain membranes showed high affinity for BD1008, haloperidol, and (+)-pentazocine (Ki = 5.06 +/- 0.40, 32.6 +/- 2.75, and 48.1 +/- 8.60 nM, respectively), which is consistent with sigma receptor pharmacology.","Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8940718/),nM,32.6,167031,DB00502,Haloperidol
,8940718,Ki,"Sites labeled by 4-[125I]PEMP in guinea pig brain membranes showed high affinity for BD1008, haloperidol, and (+)-pentazocine (Ki = 5.06 +/- 0.40, 32.6 +/- 2.75, and 48.1 +/- 8.60 nM, respectively), which is consistent with sigma receptor pharmacology.","Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8940718/),nM,48.1,167032,DB00502,Haloperidol
,8940718,Ki,"Competition binding studies of 4-[125I]PEMP in melanoma (A375) and MCF-7 breast cancer cells showed a high affinity, dose-dependent inhibition of binding with known sigma ligand N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) ethylamine, BD1008 (Ki = 5, 11 nM, respectively), supporting the labeling of sigma sites in these cells.","Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8940718/),nM,5,167033,DB00502,Haloperidol
,8940718,Ki,"Competition binding studies of 4-[125I]PEMP in melanoma (A375) and MCF-7 breast cancer cells showed a high affinity, dose-dependent inhibition of binding with known sigma ligand N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) ethylamine, BD1008 (Ki = 5, 11 nM, respectively), supporting the labeling of sigma sites in these cells.","Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8940718/),nM,11,167034,DB00502,Haloperidol
,8940718,Ki,"Haloperidol, however showed a weaker (Ki = 100-200 nM) affinity for the sites labeled by 4-[125I]PEMP in these cells.","Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8940718/),nM,100-200,167035,DB00502,Haloperidol
,9579282,Maximum selfotel levels,Maximum selfotel levels attained were 143 mumol (serum) and 4.76 mumol (CSF).,Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579282/),μM,143,170459,DB00502,Haloperidol
,9579282,Maximum selfotel levels,Maximum selfotel levels attained were 143 mumol (serum) and 4.76 mumol (CSF).,Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579282/),μM,4.76,170460,DB00502,Haloperidol
,6831826,elimination t1/2,Mean elimination t1/2 for the subjects was 17.9 +/- 6.4 (SD) hr.,Haloperidol kinetics after oral and intravenous doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),h,17.9,172393,DB00502,Haloperidol
,6831826,distribution t1/2s,"After 0.125 mg/kg IV, mean distribution t1/2s in six subjects were 0.19 +/- 0.07 and 2 +/- 1 hr, and in 12 subjects mean clearance was 11.8 +/- 2.9 ml/kg/min and mean steady-state volume of distribution was 17.8 +/- 6.5 l/kg.",Haloperidol kinetics after oral and intravenous doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),h,0.19,172394,DB00502,Haloperidol
,6831826,distribution t1/2s,"After 0.125 mg/kg IV, mean distribution t1/2s in six subjects were 0.19 +/- 0.07 and 2 +/- 1 hr, and in 12 subjects mean clearance was 11.8 +/- 2.9 ml/kg/min and mean steady-state volume of distribution was 17.8 +/- 6.5 l/kg.",Haloperidol kinetics after oral and intravenous doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),h,2,172395,DB00502,Haloperidol
,6831826,clearance,"After 0.125 mg/kg IV, mean distribution t1/2s in six subjects were 0.19 +/- 0.07 and 2 +/- 1 hr, and in 12 subjects mean clearance was 11.8 +/- 2.9 ml/kg/min and mean steady-state volume of distribution was 17.8 +/- 6.5 l/kg.",Haloperidol kinetics after oral and intravenous doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),[ml] / [kg·min],11.8,172396,DB00502,Haloperidol
,6831826,steady-state volume of distribution,"After 0.125 mg/kg IV, mean distribution t1/2s in six subjects were 0.19 +/- 0.07 and 2 +/- 1 hr, and in 12 subjects mean clearance was 11.8 +/- 2.9 ml/kg/min and mean steady-state volume of distribution was 17.8 +/- 6.5 l/kg.",Haloperidol kinetics after oral and intravenous doses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),[l] / [kg],17.8,172397,DB00502,Haloperidol
,6831826,lag time before drug absorption,"After 0.50-mg/kg oral doses in eight subjects, mean lag time before drug absorption was 0.82 +/- 0.25 hr.",Haloperidol kinetics after oral and intravenous doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),h,0.82,172398,DB00502,Haloperidol
,6831826,absorption t1/2,Mean absorption t1/2 was 0.37 +/- 0.18 hr and mean distribution t1/2 was 0.96 +/- 0.20 hr.,Haloperidol kinetics after oral and intravenous doses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),h,0.37,172399,DB00502,Haloperidol
,6831826,distribution t1/2,Mean absorption t1/2 was 0.37 +/- 0.18 hr and mean distribution t1/2 was 0.96 +/- 0.20 hr.,Haloperidol kinetics after oral and intravenous doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),h,0.96,172400,DB00502,Haloperidol
,6831826,Bioavailability,Bioavailability was 0.65 +/- 0.14 after oral doses.,Haloperidol kinetics after oral and intravenous doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831826/),,0.65,172401,DB00502,Haloperidol
,33970844,particle,"The average particle size (by DLS), entrapment efficiency and zeta potential of optimized ATX-NLC were 225.6 ± 3.04 nm, 65.91 ± 1.22 % and -52.64 mV respectively.",Appraisal of Nano-lipidic Astaxanthin cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33970844/),nm,225.6,173777,DB00502,Haloperidol
,33970844,entrapment efficiency,"The average particle size (by DLS), entrapment efficiency and zeta potential of optimized ATX-NLC were 225.6 ± 3.04 nm, 65.91 ± 1.22 % and -52.64 mV respectively.",Appraisal of Nano-lipidic Astaxanthin cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33970844/),%,65.91,173778,DB00502,Haloperidol
,33970844,zeta potential,"The average particle size (by DLS), entrapment efficiency and zeta potential of optimized ATX-NLC were 225.6 ± 3.04 nm, 65.91 ± 1.22 % and -52.64 mV respectively.",Appraisal of Nano-lipidic Astaxanthin cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33970844/),m,52.64,173779,DB00502,Haloperidol
,33970844,release,Astaxanthin release (after 24 h in simulated nasal fluid) from optimized ATX-NLC was 92.5 ± 5.42 %.,Appraisal of Nano-lipidic Astaxanthin cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33970844/),%,92.5,173780,DB00502,Haloperidol
,30247901,EC50,"From this work, 27o (VU6001376) was identified as a potent (EC50 = 50.1 nM, 50.5% GluMax) and selective mGlu4 PAM with an excellent rat DMPK profile ( in vivo rat CLp = 3.1 mL/min/kg, t1/2 = 445 min, CYP1A2 IC50 > 30 μM).","Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4). ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30247901/),nM,50.1,181479,DB00502,Haloperidol
,30247901,CLp,"From this work, 27o (VU6001376) was identified as a potent (EC50 = 50.1 nM, 50.5% GluMax) and selective mGlu4 PAM with an excellent rat DMPK profile ( in vivo rat CLp = 3.1 mL/min/kg, t1/2 = 445 min, CYP1A2 IC50 > 30 μM).","Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30247901/),[ml] / [kg·min],3.1,181480,DB00502,Haloperidol
,30247901,t1/2,"From this work, 27o (VU6001376) was identified as a potent (EC50 = 50.1 nM, 50.5% GluMax) and selective mGlu4 PAM with an excellent rat DMPK profile ( in vivo rat CLp = 3.1 mL/min/kg, t1/2 = 445 min, CYP1A2 IC50 > 30 μM).","Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30247901/),min,445,181481,DB00502,Haloperidol
>,30247901,IC50,"From this work, 27o (VU6001376) was identified as a potent (EC50 = 50.1 nM, 50.5% GluMax) and selective mGlu4 PAM with an excellent rat DMPK profile ( in vivo rat CLp = 3.1 mL/min/kg, t1/2 = 445 min, CYP1A2 IC50 > 30 μM).","Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30247901/),μM,30,181482,DB00502,Haloperidol
,28681176,oral bioavailability,"The population mean estimates for oral bioavailability, clearance and volume of distribution for an average patient were 0.86 (IIV 55%), 29.3 L/h (IIV 43%) and 1260 L (IIV 70%), respectively.",Population pharmacokinetics of haloperidol in terminally ill adult patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28681176/),,0.86,188185,DB00502,Haloperidol
,28681176,clearance,"The population mean estimates for oral bioavailability, clearance and volume of distribution for an average patient were 0.86 (IIV 55%), 29.3 L/h (IIV 43%) and 1260 L (IIV 70%), respectively.",Population pharmacokinetics of haloperidol in terminally ill adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28681176/),[l] / [h],29.3,188186,DB00502,Haloperidol
,28681176,volume of distribution,"The population mean estimates for oral bioavailability, clearance and volume of distribution for an average patient were 0.86 (IIV 55%), 29.3 L/h (IIV 43%) and 1260 L (IIV 70%), respectively.",Population pharmacokinetics of haloperidol in terminally ill adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28681176/),l,1260,188187,DB00502,Haloperidol
,28681176,terminal half-life,This resulted in an average terminal half-life of haloperidol of around 30 h.,Population pharmacokinetics of haloperidol in terminally ill adult patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28681176/),h,30,188188,DB00502,Haloperidol
,14686220,oral availability,The oral availability is 87%.,Aripiprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),%,87,189040,DB00502,Haloperidol
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,75,189041,DB00502,Haloperidol
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,94,189042,DB00502,Haloperidol
,909609,half life,The fourth phase of elimination is the slowest with a half life of 4 days.,Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/909609/),d,4,189107,DB00502,Haloperidol
,7185768,minimal steady state,For a single dose of 100 mg haloperidol decanoate monthly the minimal steady state value is about 4 ng/ml.,Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185768/),[ng] / [ml],4,192270,DB00502,Haloperidol
,17142985,Retention times,"Retention times of the BPHP and IS derivatives were 7.7 and 11.5 min, respectively.","Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142985/),min,7.7,199818,DB00502,Haloperidol
,17142985,Retention times,"Retention times of the BPHP and IS derivatives were 7.7 and 11.5 min, respectively.","Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142985/),min,11.5,199819,DB00502,Haloperidol
,17142985,detection limit,The regression equation for BPHP showed good linearity in the range of 0.01-1 mg/ml with the detection limit of 0.003 microg/ml.,"Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142985/),[μg] / [ml],0.003,199820,DB00502,Haloperidol
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,0.2,202649,DB00502,Haloperidol
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,2.2,202650,DB00502,Haloperidol
,10220126,Plasma concentrations,"Plasma concentrations of haloperidol and reduced haloperidol during grapefruit juice coadministration (9.0 +/- 3.0 and 2.6 +/- 1.4 ng/ml, respectively) were not significantly different from those before grapefruit juice coadministration (9.1 +/- 2.8 and 2.6 +/- 1.5 ng/ml) or those 1 week after its discontinuation (8.8 +/- 2.7 and 2.6 +/- 1.3 ng/ml).",Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220126/),[ng] / [ml],9.0,203210,DB00502,Haloperidol
,10220126,Plasma concentrations,"Plasma concentrations of haloperidol and reduced haloperidol during grapefruit juice coadministration (9.0 +/- 3.0 and 2.6 +/- 1.4 ng/ml, respectively) were not significantly different from those before grapefruit juice coadministration (9.1 +/- 2.8 and 2.6 +/- 1.5 ng/ml) or those 1 week after its discontinuation (8.8 +/- 2.7 and 2.6 +/- 1.3 ng/ml).",Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220126/),[ng] / [ml],2.6,203211,DB00502,Haloperidol
,10220126,Plasma concentrations,"Plasma concentrations of haloperidol and reduced haloperidol during grapefruit juice coadministration (9.0 +/- 3.0 and 2.6 +/- 1.4 ng/ml, respectively) were not significantly different from those before grapefruit juice coadministration (9.1 +/- 2.8 and 2.6 +/- 1.5 ng/ml) or those 1 week after its discontinuation (8.8 +/- 2.7 and 2.6 +/- 1.3 ng/ml).",Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220126/),[ng] / [ml],9.1,203212,DB00502,Haloperidol
,10220126,Plasma concentrations,"Plasma concentrations of haloperidol and reduced haloperidol during grapefruit juice coadministration (9.0 +/- 3.0 and 2.6 +/- 1.4 ng/ml, respectively) were not significantly different from those before grapefruit juice coadministration (9.1 +/- 2.8 and 2.6 +/- 1.5 ng/ml) or those 1 week after its discontinuation (8.8 +/- 2.7 and 2.6 +/- 1.3 ng/ml).",Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220126/),[ng] / [ml],2.6,203213,DB00502,Haloperidol
,10220126,Plasma concentrations,"Plasma concentrations of haloperidol and reduced haloperidol during grapefruit juice coadministration (9.0 +/- 3.0 and 2.6 +/- 1.4 ng/ml, respectively) were not significantly different from those before grapefruit juice coadministration (9.1 +/- 2.8 and 2.6 +/- 1.5 ng/ml) or those 1 week after its discontinuation (8.8 +/- 2.7 and 2.6 +/- 1.3 ng/ml).",Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220126/),[ng] / [ml],8.8,203214,DB00502,Haloperidol
,10220126,Plasma concentrations,"Plasma concentrations of haloperidol and reduced haloperidol during grapefruit juice coadministration (9.0 +/- 3.0 and 2.6 +/- 1.4 ng/ml, respectively) were not significantly different from those before grapefruit juice coadministration (9.1 +/- 2.8 and 2.6 +/- 1.5 ng/ml) or those 1 week after its discontinuation (8.8 +/- 2.7 and 2.6 +/- 1.3 ng/ml).",Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220126/),[ng] / [ml],2.6,203215,DB00502,Haloperidol
<,8489555,bioavailability,"However, the bioavailability was low in the rodents (< 10% in mice and hamsters and < 1% in rats) due to an extensive first-pass elimination in the hepato-portal system.",Disposition of remoxipride in different species. Species differences in metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),%,10,206092,DB00502,Haloperidol
<,8489555,bioavailability,"However, the bioavailability was low in the rodents (< 10% in mice and hamsters and < 1% in rats) due to an extensive first-pass elimination in the hepato-portal system.",Disposition of remoxipride in different species. Species differences in metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),%,1,206093,DB00502,Haloperidol
>,8489555,bioavailability,"In dogs and humans, clearance values were low and the bioavailability high (> 90%).",Disposition of remoxipride in different species. Species differences in metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),%,90,206094,DB00502,Haloperidol
,8489555,volume of distribution (Vss),"In accordance with the binding data, the volume of distribution (Vss) was higher in rodents (3-6 l/kg) than in dogs (1.6 l/kg) and man (0.7 l/kg).",Disposition of remoxipride in different species. Species differences in metabolism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),[l] / [kg],3-6,206095,DB00502,Haloperidol
,8489555,volume of distribution (Vss),"In accordance with the binding data, the volume of distribution (Vss) was higher in rodents (3-6 l/kg) than in dogs (1.6 l/kg) and man (0.7 l/kg).",Disposition of remoxipride in different species. Species differences in metabolism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),[l] / [kg],1.6,206096,DB00502,Haloperidol
,8489555,volume of distribution (Vss),"In accordance with the binding data, the volume of distribution (Vss) was higher in rodents (3-6 l/kg) than in dogs (1.6 l/kg) and man (0.7 l/kg).",Disposition of remoxipride in different species. Species differences in metabolism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),[l] / [kg],0.7,206097,DB00502,Haloperidol
,8489555,t1/2,Studies in dogs with 14C-remoxipride showed that the compound was rapidly distributed to tissues and eliminated at rates similar to that in plasma (t1/2 3-4 h).,Disposition of remoxipride in different species. Species differences in metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489555/),h,3-4,206098,DB00502,Haloperidol
,1604422,total brain uptake,Medicated schizophrenics showed a total brain uptake of 4.0% and had a significant clearance of [18F]haloperidol from brain and a higher concentration of [18F]haloperidol in plasma.,Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F]haloperidol. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1604422/),%,4.0,207486,DB00502,Haloperidol
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,2.207,214678,DB00502,Haloperidol
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,0.093,214679,DB00502,Haloperidol
,3731135,half-life,"The serum haloperidol clearance rate was accelerated in patients taking rifampicin, with a shortened half-life (4.9 h) compared with the control group (9.4 h).",Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731135/),h,4.9,215599,DB00502,Haloperidol
,3731135,half-life,"The serum haloperidol clearance rate was accelerated in patients taking rifampicin, with a shortened half-life (4.9 h) compared with the control group (9.4 h).",Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731135/),h,9.4,215600,DB00502,Haloperidol
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],16.7,216921,DB00502,Haloperidol
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],8.9,216922,DB00502,Haloperidol
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],9.9,216923,DB00502,Haloperidol
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],3.6,216924,DB00502,Haloperidol
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],1.8,216925,DB00502,Haloperidol
,26253621,elimination half-life,The elimination half-life in the striatum (61 min) correlates with the decrease in the psychostimulant effect after 60 min.,Concentrations of MDPV in rat striatum correlate with the psychostimulant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26253621/),min,61,217024,DB00502,Haloperidol
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,16.4,222423,DB00502,Haloperidol
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.541,222424,DB00502,Haloperidol
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,28.0,222425,DB00502,Haloperidol
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],2.00,222426,DB00502,Haloperidol
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,24.0,222427,DB00502,Haloperidol
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.106,222428,DB00502,Haloperidol
,8453823,time to reach peak plasma concentrations,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),h,1.1 to 3.6,224037,DB00502,Haloperidol
,8453823,elimination half-life,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),h,9.1 to 17.4,224038,DB00502,Haloperidol
,8453823,clearance,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[l] / [h],8.7 to 53.3,224039,DB00502,Haloperidol
,8453823,volume of distribution,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[l] / [kg],1.6 to 7.3,224040,DB00502,Haloperidol
,8453823,minimum concentration,"In the treatment of patients with refractory schizophrenia, a minimum concentration of 350 micrograms/L was suggested as needed.",Pharmacokinetics and pharmacodynamics of clozapine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[μg] / [l],350,224041,DB00502,Haloperidol
,9200764,plasma,Levomepromazine (n = 17) significantly (p < 0.001) increased plasma concentrations of bromperidol (7.3 +/- 4.1 versus 10.2 +/- 4.8 ng/ml) and reduced bromperidol (1.8 +/- 1.4 versus 4.5 +/- 3.3 ng/ml).,"Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200764/),,10,227565,DB00502,Haloperidol
,9200764,plasma concentrations,"Thioridazine (n = 16) did not significantly change plasma concentrations of bromperidol (9.1 +/- 5.7 versus 8.6 +/- 5.5 ng/ml), while those of reduced bromperidol could not be measured because of interfering peaks.","Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200764/),,8,227566,DB00502,Haloperidol
,2885172,T 1/2,"Mean value of T 1/2 of clopenthixol decanoate and haloperidol decanoate are 19 and 21 days, respectively, they thereby justify monthly administration.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,19,227924,DB00502,Haloperidol
,2885172,T 1/2,"Mean value of T 1/2 of clopenthixol decanoate and haloperidol decanoate are 19 and 21 days, respectively, they thereby justify monthly administration.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,21,227925,DB00502,Haloperidol
,2885172,half-lives,"Flupenthixol decanoate and fluphenazine enanthate should be injected with dosing intervals of 3 and 1 weeks, respectively in respect with their half-lives: 17 and 4 days.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,17,227926,DB00502,Haloperidol
,2885172,half-lives,"Flupenthixol decanoate and fluphenazine enanthate should be injected with dosing intervals of 3 and 1 weeks, respectively in respect with their half-lives: 17 and 4 days.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,4,227927,DB00502,Haloperidol
,2885172,half-life,"Fluphenazine decanoate have a half-life of 14 days, however, the longer time the treatment, the longer the apparent half-life, suggesting to reduce the dose or to enlarge the dosing interval.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,14,227928,DB00502,Haloperidol
,19192440,half-life,"Its unique pharmacokinetic profile as an oral drug with long half-life (2-7 weeks), low cost, and low induction of extrapyramidal symptoms warrants further investigation, particularly in psychiatric patients with low adherence to treatment.",Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192440/),weeks,2-7,233080,DB00502,Haloperidol
,1579624,elimination half-life,The mean elimination half-life of 54.8 h determined by model dependent analysis was similar to the mean elimination half-life of 59.9 h determined by model independent analysis.,Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1579624/),h,54.8,233925,DB00502,Haloperidol
,1579624,elimination half-life,The mean elimination half-life of 54.8 h determined by model dependent analysis was similar to the mean elimination half-life of 59.9 h determined by model independent analysis.,Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1579624/),h,59.9,233926,DB00502,Haloperidol
,1579624,plasma clearance,The mean plasma clearance was 21.71/h and the mean volume of distribution during the distribution phase was 1754.3 1.,Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1579624/),1/[h],21.71,233927,DB00502,Haloperidol
,1579624,volume of distribution during the distribution phase,The mean plasma clearance was 21.71/h and the mean volume of distribution during the distribution phase was 1754.3 1.,Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1579624/),1,1754.3,233928,DB00502,Haloperidol
,1579624,bioavailability,"After oral dosing, bioavailability of haloperidol was 35 +/- 8%, suggesting extensive first pass metabolism.",Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1579624/),%,35,233929,DB00502,Haloperidol
,7846204,serum concentrations,"The serum concentrations in nmol/L of perphenazine and haloperidol (week 24) were 0.8-15.9 and 2.3-46.7, respectively.",A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7846204/),[nM] / [l],0,238154,DB00502,Haloperidol
,7846204,serum concentrations,"The serum concentrations in nmol/L of perphenazine and haloperidol (week 24) were 0.8-15.9 and 2.3-46.7, respectively.",A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7846204/),[nM] / [l],2.3-46.7,238155,DB00502,Haloperidol
,23138261,concentrations at half-maximal inhibition,"Plasma haloperidol concentrations at half-maximal inhibition were 0.791 and 0.650 ng/ml, in putamen and caudate nucleus.","Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138261/),[ng] / [ml],0.791,248007,DB00502,Haloperidol
,23138261,concentrations at half-maximal inhibition,"Plasma haloperidol concentrations at half-maximal inhibition were 0.791 and 0.650 ng/ml, in putamen and caudate nucleus.","Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138261/),[ng] / [ml],0.650,248008,DB00502,Haloperidol
,17038888,elimination constant,"The elimination constant in brain tissue was determined to be 0.00447 [1/h], resulting in a t1/2 of 6.5 days for the mean patient in the population investigated (n = 19).",Pharmacokinetic characterization of amantadine in human brain tissue. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038888/),[1] / [h],0.00447,254591,DB00502,Haloperidol
,17038888,t1/2,"The elimination constant in brain tissue was determined to be 0.00447 [1/h], resulting in a t1/2 of 6.5 days for the mean patient in the population investigated (n = 19).",Pharmacokinetic characterization of amantadine in human brain tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038888/),d,6.5,254592,DB00502,Haloperidol
,17038888,apparent volume of distribution,An estimate of 65.5 L was obtained for the apparent volume of distribution.,Pharmacokinetic characterization of amantadine in human brain tissue. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038888/),l,65.5,254593,DB00502,Haloperidol
,8371156,Nonspecific binding,"Nonspecific binding, defined using 1 mg/kg (2.66 mumol/kg) of haloperidol, was approximately 30% of total binding 1 hr after injection of radiotracer.",[3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8371156/),%,30,254836,DB00502,Haloperidol
,8371156,ID50,"Administration of DuP 734 potently antagonized the binding of [3H]DuP 734 and [3H](+)-SKF 10,047 to brain sigma receptors in vivo with ID50 values of 0.02 and 0.07 mg/kg (0.07 and 0.25 mumol/kg), respectively.",[3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8371156/),[mg] / [kg],0.02,254837,DB00502,Haloperidol
,8371156,ID50,"Administration of DuP 734 potently antagonized the binding of [3H]DuP 734 and [3H](+)-SKF 10,047 to brain sigma receptors in vivo with ID50 values of 0.02 and 0.07 mg/kg (0.07 and 0.25 mumol/kg), respectively.",[3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8371156/),[mg] / [kg],0.07,254838,DB00502,Haloperidol
,8371156,ID50,"Administration of DuP 734 potently antagonized the binding of [3H]DuP 734 and [3H](+)-SKF 10,047 to brain sigma receptors in vivo with ID50 values of 0.02 and 0.07 mg/kg (0.07 and 0.25 mumol/kg), respectively.",[3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8371156/),[μM] / [kg],0.07,254839,DB00502,Haloperidol
,8371156,ID50,"Administration of DuP 734 potently antagonized the binding of [3H]DuP 734 and [3H](+)-SKF 10,047 to brain sigma receptors in vivo with ID50 values of 0.02 and 0.07 mg/kg (0.07 and 0.25 mumol/kg), respectively.",[3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8371156/),[μM] / [kg],0.25,254840,DB00502,Haloperidol
,8371156,IC50,"However, (+)-SKF 10,047, which possess a high affinity (IC50 = 22.5 nM) for [3H]DuP 734 binding in vitro, failed to displace [3H]DuP 734 binding in vivo.",[3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8371156/),nM,22.5,254841,DB00502,Haloperidol
,16506267,detection limit,The regression equation for CPHP showed a good linearity in the range of 0.03-1 microg/mL with a detection limit of 0.008 microg/mL.,"Sensitive determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, in a rat biological sample by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506267/),[μg] / [ml],0.008,255367,DB00502,Haloperidol
,2056148,ratios at steady state,"Plasma RHAL/HAL ratios at steady state during HAL treatment were significantly greater than the HAL/RHAL ratios after repeated reduced HAL administration (0.51 +/- 0.12 vs. 0.16 +/- 0.04 SD, p less than 0.0005).",Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2056148/),sd,0.51,256034,DB00502,Haloperidol
,2056148,ratios at steady state,"Plasma RHAL/HAL ratios at steady state during HAL treatment were significantly greater than the HAL/RHAL ratios after repeated reduced HAL administration (0.51 +/- 0.12 vs. 0.16 +/- 0.04 SD, p less than 0.0005).",Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2056148/),sd,0.16,256035,DB00502,Haloperidol
,8486817,steady-state concentrations,Forty hospitalized patients suffering from an acute exacerbation of schizophrenia were treated for 2 weeks with fixed oral doses of haloperidol ranging from 10 to 70 mg/day (0.13 to 0.95 mg/kg/day) that produced mean steady-state concentrations between 4.5 and 55.4 ng/ml.,Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8486817/),[ng] / [ml],4.5 and 55.4,256329,DB00502,Haloperidol
,16915578,T(max),"The T(max) (3.9 +/- 0.9 h), clearance (1.37 +/- 0.52 ml/h/kg), and t(1/2) (20.4 +/- 3.7 h) obtained in our study are comparable to those in previous Caucasian studies, although pharmacokinetic profiles were affected by the BP dose.",Pharmacokinetic parameters of bromperidol in Korean subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16915578/),h,3.9,259964,DB00502,Haloperidol
,16915578,clearance,"The T(max) (3.9 +/- 0.9 h), clearance (1.37 +/- 0.52 ml/h/kg), and t(1/2) (20.4 +/- 3.7 h) obtained in our study are comparable to those in previous Caucasian studies, although pharmacokinetic profiles were affected by the BP dose.",Pharmacokinetic parameters of bromperidol in Korean subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16915578/),[ml] / [h·kg],1.37,259965,DB00502,Haloperidol
,16915578,t(1/2),"The T(max) (3.9 +/- 0.9 h), clearance (1.37 +/- 0.52 ml/h/kg), and t(1/2) (20.4 +/- 3.7 h) obtained in our study are comparable to those in previous Caucasian studies, although pharmacokinetic profiles were affected by the BP dose.",Pharmacokinetic parameters of bromperidol in Korean subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16915578/),h,20.4,259966,DB00502,Haloperidol
,28844183,PDI,"Optimized formulation (A10) showed spherical droplets with mean diameter of 60.00 ± 15 nm, PDI of 0.121 ± 0.053, and zeta potential values of -24.40 ± 0.16 mV.",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),,0.121,260891,DB00502,Haloperidol
,28844183,zeta potential,"Optimized formulation (A10) showed spherical droplets with mean diameter of 60.00 ± 15 nm, PDI of 0.121 ± 0.053, and zeta potential values of -24.40 ± 0.16 mV.",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),mv,-24.40,260892,DB00502,Haloperidol
,28844183,transmittance,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),%,100.50,260893,DB00502,Haloperidol
,28844183,refractive index,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),,1.41,260894,DB00502,Haloperidol
,28844183,viscosity,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),cp,30.54,260895,DB00502,Haloperidol
,15113555,flow-rate,"The mobile phases consisted of phosphate buffer (0.02M, pH 4.6), perchloric acid (60%) and acetonitrile (54:1:45 (v/v)) and was delivered at a flow-rate of 0.6ml/min.",Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113555/),[ml] / [min],0.6,261720,DB00502,Haloperidol
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,298.1,266332,DB00502,Haloperidol
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,154.1,266333,DB00502,Haloperidol
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,376.2,266334,DB00502,Haloperidol
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,165.2,266335,DB00502,Haloperidol
,11149673,receptor,"In humans, the striatal D2/D3 receptor occupancy was 0.27+/-0.085 and the in vivo Kd for haloperidol was 0.25+/-0.1 nmol/L, which is comparable to Kd values as obtained from in vitro studies.",In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149673/),,0.27,270562,DB00502,Haloperidol
,11149673,occupancy,"In humans, the striatal D2/D3 receptor occupancy was 0.27+/-0.085 and the in vivo Kd for haloperidol was 0.25+/-0.1 nmol/L, which is comparable to Kd values as obtained from in vitro studies.",In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149673/),,0.27,270563,DB00502,Haloperidol
,11149673,Kd,"In humans, the striatal D2/D3 receptor occupancy was 0.27+/-0.085 and the in vivo Kd for haloperidol was 0.25+/-0.1 nmol/L, which is comparable to Kd values as obtained from in vitro studies.",In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149673/),[nM] / [l],0.25,270564,DB00502,Haloperidol
,1432610,minimal,"The observed values of minimal and maximal concentrations in plasma (Cmin and Cmax, respectively) varied widely among patients: 3.0-22.9 and 6.2-32.7 ng/mL for HL and 2.8-21.4 and 5.7-33.3 ng/ml for RHL, respectively.",Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432610/),[ng] / [ml],3.0-22.9,273960,DB00502,Haloperidol
,1432610,maximal concentrations in plasma (Cmin,"The observed values of minimal and maximal concentrations in plasma (Cmin and Cmax, respectively) varied widely among patients: 3.0-22.9 and 6.2-32.7 ng/mL for HL and 2.8-21.4 and 5.7-33.3 ng/ml for RHL, respectively.",Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432610/),[ng] / [ml],3.0-22.9,273961,DB00502,Haloperidol
,1432610,maximal concentrations in plasma (Cmin,"The observed values of minimal and maximal concentrations in plasma (Cmin and Cmax, respectively) varied widely among patients: 3.0-22.9 and 6.2-32.7 ng/mL for HL and 2.8-21.4 and 5.7-33.3 ng/ml for RHL, respectively.",Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432610/),[ng] / [ml],6.2-32.7,273962,DB00502,Haloperidol
,1432610,maximal concentrations in plasma (Cmin,"The observed values of minimal and maximal concentrations in plasma (Cmin and Cmax, respectively) varied widely among patients: 3.0-22.9 and 6.2-32.7 ng/mL for HL and 2.8-21.4 and 5.7-33.3 ng/ml for RHL, respectively.",Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432610/),[ng] / [ml],2.8-21.4,273963,DB00502,Haloperidol
,1432610,Cmax,"The observed values of minimal and maximal concentrations in plasma (Cmin and Cmax, respectively) varied widely among patients: 3.0-22.9 and 6.2-32.7 ng/mL for HL and 2.8-21.4 and 5.7-33.3 ng/ml for RHL, respectively.",Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432610/),[ng] / [ml],6.2-32.7,273964,DB00502,Haloperidol
,1432610,Cmax,"The observed values of minimal and maximal concentrations in plasma (Cmin and Cmax, respectively) varied widely among patients: 3.0-22.9 and 6.2-32.7 ng/mL for HL and 2.8-21.4 and 5.7-33.3 ng/ml for RHL, respectively.",Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432610/),[ng] / [ml],2.8-21.4,273965,DB00502,Haloperidol
